Top Investing Today
  • Investing
  • Politics
  • Stock
  • Economy
  • Editor’s Pick
  • Investing
  • Politics
  • Stock
  • Economy
  • Editor’s Pick
No Result
View All Result
Top Investing Today
No Result
View All Result
Home News

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

BoldThemes by BoldThemes
November 26, 2024
in News, Politics
0
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS
Previous Post

Stop funding the woke and the stupid

Next Post

Private 5G to Drive 63% CAGR in In-Building Wireless Market, Narrowing the Gap with DAS by 2029

BoldThemes

BoldThemes

Next Post
Private 5G to Drive 63% CAGR in In-Building Wireless Market, Narrowing the Gap with DAS by 2029

Private 5G to Drive 63% CAGR in In-Building Wireless Market, Narrowing the Gap with DAS by 2029

  • Trending
  • Comments
  • Latest
The Connectivity Standards Alliance Product Security Working Group Launches the IoT Device Security Specification 1.0

The Connectivity Standards Alliance Product Security Working Group Launches the IoT Device Security Specification 1.0

March 19, 2024
Israel says UN ‘deceiving’ world over aid delays to Gaza

Israel says UN ‘deceiving’ world over aid delays to Gaza

March 28, 2024
Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

February 6, 2024
Gold and Silver Set to Smash Records: Could 2024 Be Their Biggest Year Yet?

Gold and Silver Set to Smash Records: Could 2024 Be Their Biggest Year Yet?

May 17, 2024
Smart Strategies for Reducing the IoT Attack Surface

Smart Strategies for Reducing the IoT Attack Surface

0
Amid growing criticism of Biden foreign policy, experts credit wins while leaving room for improvement

Amid growing criticism of Biden foreign policy, experts credit wins while leaving room for improvement

0
Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

Conservative backlash to Israel aid bill could force Johnson to seek Democrat support again

0
Precision Manufacturing For Sensitive Equipment With CNC Machining

Precision Manufacturing For Sensitive Equipment With CNC Machining

0
Smart Strategies for Reducing the IoT Attack Surface

Smart Strategies for Reducing the IoT Attack Surface

May 14, 2025

Key Biden agency dropped $60K on overseas conference with DEI workshop: ‘Should never happen’

May 14, 2025

‘DOGE caucus is dead,’ House Democrat declares

May 14, 2025

Trump says ‘there’s something wrong’ with top Democrat he’s known ‘a long time’

May 14, 2025
Enter Your Information Below To Receive Trading Ideas and Latest News

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    Recent News

    Smart Strategies for Reducing the IoT Attack Surface

    Smart Strategies for Reducing the IoT Attack Surface

    May 14, 2025

    Key Biden agency dropped $60K on overseas conference with DEI workshop: ‘Should never happen’

    May 14, 2025

    ‘DOGE caucus is dead,’ House Democrat declares

    May 14, 2025

    Trump says ‘there’s something wrong’ with top Democrat he’s known ‘a long time’

    May 14, 2025
    • About Us
    • Privacy Policy
    • Terms & Conditions
    • Contact

    Copyright © 2024 Topinvestingtoday.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Politics
    • Stock
    • Economy
    • Editor’s Pick

    Copyright © 2024 Topinvestingtoday.com. All Rights Reserved.